Long Beach Obesity & Type 2 Diabetes Clinical Trial

Obesity & Type 2 Diabetes Clinical Trial

Type 2 diabetes is a chronic illness that is closely associated with obesity. The excessive amount of visceral fat causes the release of inflammatory substances, which disrupts insulin activity. This makes it difficult to control blood sugar, even with the use of traditional drugs. New treatments are being researched in response to this challenge. Paragon RX Clinical is conducting a controlled clinical trial in Long Beach to evaluate an injectable therapy targeting incretin-based mechanisms administered once a week.

An Overview of the Investigational Injectable Treatment

Before consenting to participate in this clinical trial, it is essential to understand the pharmacological rationale behind it. The study involves research on an investigational medicinal product administered as an injectable once a week. It acts by incretin mimetics, a type of agent that imitates the action of natural gut hormones, such as Glucagon-Like Peptide-1 (GLP-1).

The intestines normally secrete these hormones after you take a meal to regulate metabolism in three main ways, namely, to cause the pancreas to secrete insulin in response to glucose, to inhibit inappropriate secretion of glucagon by the liver, and to slow gastric emptying to increase the sensation of fullness.

The incretin effect is compromised or reduced in obesity and Type 2 diabetes patients. This reduction leads to an inability to regulate blood glucose levels and body weight, necessitating pharmacological correction of the metabolic imbalance. The trial experimental treatment is designed to address high blood sugar and excess body fat.

The treatment will reduce HbA1c, a significant indicator of mean blood glucose in three months, and will also achieve a substantial weight loss by acting on the incretin pathway. Visceral fat reduction is essential, as it contributes to improving insulin sensitivity and overall metabolic health.

The study identifies the capability of the therapy to result in a five to ten percent reduction in total body weight, which is associated with a lower cardiovascular risk. The researchers also monitor secondary markers, including lipid profiles, waist circumference, and blood pressure, to have a complete evaluation of safety and efficacy.

It is an investigational treatment, meaning the FDA has not yet approved it for this indication. The trial is conducted based on an Investigational New Drug (IND) application, which permits the use of the drug in research only.

The research is randomized and placebo-controlled, which gives scientifically valid results. These subjects will be randomly selected to be on either the active drug or a placebo, which is an inactive substance with no curative impact. This design is such that any improvement observed can be attributed to the investigational therapy, rather than to other factors or the placebo effect.

Understanding Eligibility for This Clinical Trial

The inclusion and exclusion criteria are stringent, ensuring the safety of participants and the validity of data collection. These are the needs that cannot be compromised and should be followed strictly by all participants. They include the following:

Inclusion Criteria

The participants will be aged 18-75 years. The range allows the researcher to conclude the safety and effectiveness of the drug in an adult population in general, but not in pediatric and elderly populations, where metabolism and organ function can differ.

What to Know About the Participant Experience

Participating in a clinical trial means being bound to a systematic procedure, which typically lasts between 56 and 72 weeks. The trial is divided into operational phases, which include the following:

Prescreening and Screening

The process begins with a prescreening interview conducted by a research coordinator to verify age, diagnosis, and medication history. In the event of initial requirements, you will be subject to an elaborate screening visit.

The process of Informed Consent takes place during screening. This legal and ethical document describes:

Treatment and Randomization Process

The eligible participants will be randomly allocated either to the active drug or to the placebo. The participant and the clinical personnel are not aware of the assignment to avoid bias. The participants are trained on self-administered injections. The dosage is gradually increased in the first weeks to minimize gastrointestinal side effects.

Maintenance Phase

Visits are conducted regularly, every two to four weeks, to ensure safety and gather data. Clinical personnel measure vital signs, weight, and waist circumference and discuss adverse events. Blood tests are also done periodically to check the HbA1c and other markers.

Lifestyle support is also a part of the protocol. It provides information about diet and exercise. Lifestyle modifications are most effective when combined with medication therapy.

Understanding Pros and Cons of Participation

There are several potential benefits to participation. Among the advantages is the free and intensive medical monitoring. Regular evaluation of metabolic and cardiovascular well-being provides information that is not typically included in clinical care. The participants will have access to new therapies that are not commercially available and may be particularly beneficial for those who have not achieved glycemic goals with current medications.

The study medication, laboratory tests, and physician visits are provided at no cost. Participants can also be compensated for time and travel expenses, as approved by the IRB. The involvement also aids in scientific research, as it facilitates the validation of new treatments for obesity and Type 2 diabetes that may benefit people worldwide.

Find an Efficient Obesity and Type 2 Diabetes Clinical Trial Near Me

The treatment of obesity and Type 2 diabetes is complicated and needs sophisticated treatment methods. Paragon RX Clinical is conducting a clinical trial in Long Beach to evaluate investigational injectables based on the incretin hormone, which helps control blood sugar and promote weight loss. The research is conducted under rigorous eligibility standards and safety measures to ensure the safety of participants and produce high-quality data that can inform future treatment. The participants have the advantage of being closely monitored by the medical team, receiving state-of-the-art treatment, and having the opportunity to contribute to medical research. If you meet the eligibility requirements and are interested in exploring this investigational treatment, please contact us today at 714-539-3013 to speak with a research coordinator, confirm your eligibility, and initiate the screening process.